{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:54:36Z","timestamp":1792814076188,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since 2017, hormone-negative pituitary neuroendocrine tumors expressing the steroidogenic factor SF1 have been recognized as gonadotroph tumors (GnPT) but have been poorly studied. To further characterize their bio-clinical spectrum, 54 GnPT defined by immunostaining for FSH and\/or LH (group 1, <jats:italic>n<\/jats:italic> = 41) or SF1 only (group 2, <jats:italic>n<\/jats:italic> = 13) were compared and studied for <jats:italic>SF1<\/jats:italic>, <jats:italic>\u03b2FSH<\/jats:italic>, <jats:italic>\u03b2LH<\/jats:italic>, <jats:italic>CCNA2<\/jats:italic>, <jats:italic>CCNB1<\/jats:italic>, <jats:italic>CCND1<\/jats:italic>, <jats:italic>caspase 3<\/jats:italic>, <jats:italic>D2R<\/jats:italic>, and <jats:italic>AIP<\/jats:italic> gene expression by qRT-PCR. Immunohistochemistry for AIP and\/or D2R was performed in representative cases. Overall, patients were significantly younger in group 1 (<jats:italic>P<\/jats:italic> = 0.040 vs group 2), with a similar trend excluding recurrent cases (<jats:italic>P<\/jats:italic> = 0.078), and no significant difference in gender, tumor size, invasion or Ki67. <jats:italic>SF1<\/jats:italic> expression was similar in both groups but negatively correlated with the patient\u2019s age (<jats:italic>P<\/jats:italic> = 0.013) and positively correlated with <jats:italic>\u03b2LH<\/jats:italic> (<jats:italic>P<\/jats:italic> &lt; 0.001) expression. <jats:italic>Beta-FSH<\/jats:italic> and <jats:italic>AIP<\/jats:italic> were significantly higher in group 1 (<jats:italic>P<\/jats:italic> = 0.042 and <jats:italic>P<\/jats:italic> = 0.024, respectively). Ki67 was unrelated to gonadotroph markers but positively correlated with <jats:italic>CCNB1<\/jats:italic> (<jats:italic>P<\/jats:italic> = 0.001) and negatively correlated with <jats:italic>CCND1<\/jats:italic> (<jats:italic>P<\/jats:italic> = 0.008). <jats:italic>D2R<\/jats:italic> and <jats:italic>AIP<\/jats:italic> were strongly correlated with each other (<jats:italic>P<\/jats:italic> &lt; 0.001), and both positively correlated with <jats:italic>SF1<\/jats:italic>, <jats:italic>\u03b2FSH<\/jats:italic>, <jats:italic>\u03b2LH<\/jats:italic>, <jats:italic>and CCND1<\/jats:italic>. AIP immunopositivity was frequently observed in both groups, with a similar median score, and unrelated to Ki67. D2R immunostaining was best detected with a polyclonal antibody and mostly cytoplasmic. This study indicates that hormone-negative GnPT tend to occur in older patients but do not significantly differ from other GnPT in terms of invasion or proliferation. It also points out the current limits of D2R immunostaining in such tumors.<\/jats:p>","DOI":"10.1007\/s12022-023-09794-w","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T09:02:15Z","timestamp":1702544535000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical and Molecular Characteristics of Gonadotroph Pituitary Tumors According to the WHO Classification"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4710-9877","authenticated-orcid":false,"given":"Francesca","family":"Carbonara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1066-0064","authenticated-orcid":false,"given":"Tiziana","family":"Feola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6223-9952","authenticated-orcid":false,"given":"Francesca","family":"Gianno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-6855","authenticated-orcid":false,"given":"Michela Anna","family":"Polidoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0141","authenticated-orcid":false,"given":"Rosa Maria","family":"Di Crescenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0708-8282","authenticated-orcid":false,"given":"Antonietta","family":"Arcella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-7446","authenticated-orcid":false,"given":"Michelangelo","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1643-5530","authenticated-orcid":false,"given":"Roberta","family":"Morace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-1761","authenticated-orcid":false,"given":"Dario","family":"de Alcubierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-5461","authenticated-orcid":false,"given":"Vincenzo","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5382-2380","authenticated-orcid":false,"given":"Felice","family":"Giangaspero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-8997","authenticated-orcid":false,"given":"Marie-Lise","family":"Jaffrain-Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"9794_CR1","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1210\/jc.2014-2362","volume":"99","author":"G Ntali","year":"2014","unstructured":"Ntali G, Capatina C, Grossman A, Karavitaki N (2014) Clinical review: Functioning gonadotroph adenomas. J Clin Endocrinol Metab 99:4423\u20134433. https:\/\/doi.org\/10.1210\/jc.2014-2362","journal-title":"J Clin Endocrinol Metab"},{"key":"9794_CR2","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1210\/jc.2018-00688","volume":"104","author":"J Drummond","year":"2019","unstructured":"Drummond J, Roncaroli F, Grossman AB, Korbonits M (2019) Clinical and Pathological Aspects of Silent Pituitary Adenomas. J Clin Endocrinol Metab 104:2473\u20132489. https:\/\/doi.org\/10.1210\/jc.2018-00688","journal-title":"J Clin Endocrinol Metab"},{"key":"9794_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","volume":"28","author":"O Mete","year":"2017","unstructured":"Mete O, Lopes MB (2017) Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol 28:228\u2013243. https:\/\/doi.org\/10.1007\/s12022-017-9498-z","journal-title":"Endocr Pathol"},{"key":"9794_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol 33:6\u201326. https:\/\/doi.org\/10.1007\/s12022-022-09703-7","journal-title":"Endocr Pathol"},{"key":"9794_CR5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/s41379-018-0016-8","volume":"31","author":"O Mete","year":"2018","unstructured":"Mete O, Cintosun A, Pressman I, Asa SL (2018) Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol 31:900\u2013909. https:\/\/doi.org\/10.1038\/s41379-018-0016-8","journal-title":"Mod Pathol"},{"key":"9794_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00428-019-02655-0","volume":"475","author":"C Villa","year":"2019","unstructured":"Villa C, Vasiljevic A, Jaffrain-Rea ML, Ansorge O, Asioli S, Barresi V, Chinezu L, Gardiman MP, Lania A, Lapshina AM, Poliani L, Reiniger L, Righi A, Saeger W, Soukup J, Theodoropoulou M, Uccella S, Trouillas J, Roncaroli F (2019) A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Arch 475:687\u2013692. https:\/\/doi.org\/10.1007\/s00428-019-02655-0","journal-title":"Virchows Arch"},{"key":"9794_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12022-015-9398-z","volume":"26","author":"H Nishioka","year":"2015","unstructured":"Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, Fukuhara N, Yamaguchi-Okada M, Takeuchi Y, Yamada S (2015) The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocr Pathol 26:349\u2013355. https:\/\/doi.org\/10.1007\/s12022-015-9398-z","journal-title":"Endocr Pathol"},{"key":"9794_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000514862","volume":"112","author":"A Spada","year":"2022","unstructured":"Spada A, Mantovani G, Lania AG, Treppiedi D, Mangili F, Catalano R, Carosi G, Sala E, Peverelli E (2022) Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior. Neuroendocrinology 112:15\u201333. https:\/\/doi.org\/10.1159\/000514862","journal-title":"Neuroendocrinology"},{"key":"9794_CR9","doi-asserted-by":"publisher","first-page":"D11","DOI":"10.1530\/EJE-21-0344","volume":"185","author":"Y Greenman","year":"2021","unstructured":"Greenman Y, Bronstein MD (2021) Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma. Eur J Endocrinol 185:D11\u2013D20. https:\/\/doi.org\/10.1530\/EJE-21-0344","journal-title":"Eur J Endocrinol"},{"key":"9794_CR10","doi-asserted-by":"publisher","first-page":"101685","DOI":"10.1016\/j.beem.2022.101685","volume":"36","author":"N Even-Zohar","year":"2022","unstructured":"Even-Zohar N, Greenman Y (2022) Current medical treatment and perspective in gonadotroph tumors. Best Pract Res Clin Endocrinol Metab 36:101685. https:\/\/doi.org\/10.1016\/j.beem.2022.101685","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"9794_CR11","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1210\/jc.2003-030859","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, Colao A, Annunziato L, Lombardi G (2004) Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 89:1674\u20131683. https:\/\/doi.org\/10.1210\/jc.2003-030859","journal-title":"J Clin Endocrinol Metab"},{"key":"9794_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/cen.12684","volume":"82","author":"L Vieira Neto","year":"2015","unstructured":"Vieira Neto L, Wildemberg LE, Moraes AB, Colli LM, Kasuki L, Marques NV, Gasparetto EL, de Castro M, Takiya CM, Gadelha MR (2015) Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy. Clin Endocrinol (Oxf) 82:739\u2013746. https:\/\/doi.org\/10.1111\/cen.12684","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9794_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1530\/EJE-16-0206","volume":"175","author":"Y Greenman","year":"2016","unstructured":"Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonas-Kimchi T, Yuan X, Gertych A, Shimon I, Ram Z, Melmed S, Stern N (2016) Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol 175:63\u201372. https:\/\/doi.org\/10.1530\/EJE-16-0206","journal-title":"Eur J Endocrinol"},{"key":"9794_CR14","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1126\/science.1126100","volume":"312","author":"O Vierimaa","year":"2006","unstructured":"Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TML, Salmela PI, Paschke R, G\u00fcndogdu S, De Menis E, M\u00e4kinen MJ, Launonen V, Karhu A, Aaltonen LA (2006) Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312:1228\u20131230. https:\/\/doi.org\/10.1126\/science.1126100","journal-title":"Science"},{"key":"9794_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1210\/er.2012-1013","volume":"34","author":"A Beckers","year":"2013","unstructured":"Beckers A, Aaltonen LA, Daly AF, Karhu A (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34:239\u2013277. https:\/\/doi.org\/10.1210\/er.2012-1013","journal-title":"Endocr Rev"},{"key":"9794_CR16","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1210\/endrev\/bnaa006","volume":"41","author":"V Srirangam Nadhamuni","year":"2020","unstructured":"Srirangam Nadhamuni V, Korbonits M (2020) Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms. Endocr Rev 41:821\u2013846. https:\/\/doi.org\/10.1210\/endrev\/bnaa006","journal-title":"Endocr Rev"},{"key":"9794_CR17","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1210\/jc.2007-2611","volume":"93","author":"CA Leontiou","year":"2008","unstructured":"Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JAH, Popovic V, Ribeiro-Oliveira A, Gadelha MR, Monson JP, Akker SA, Davis JRE, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M (2008) The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 93:2390\u20132401. https:\/\/doi.org\/10.1210\/jc.2007-2611","journal-title":"J Clin Endocrinol Metab"},{"key":"9794_CR18","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1677\/ERC-09-0094","volume":"16","author":"M-L Jaffrain-Rea","year":"2009","unstructured":"Jaffrain-Rea M-L, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen J-F, D\u2019Innocenzo E, Barlier A, Giangaspero F, Esposito V, Ventura L, Arcella A, Theodoropoulou M, Naves LA, Fajardo C, Zacharieva S, Rohmer V, Brue T, Gulino A, Cantore G, Alesse E, Beckers A (2009) Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer 16:1029\u20131043. https:\/\/doi.org\/10.1677\/ERC-09-0094","journal-title":"Endocr Relat Cancer"},{"key":"9794_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000322787","volume":"94","author":"K Jomori","year":"2011","unstructured":"Kasuki Jomori de Pinho L, Vieira Neto L, Armondi Wildemberg LE, Gasparetto EL, Marcondes J, de Almeida Nunes B, Takiya CM, Gadelha MR (2011) Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology 94:39\u201348. https:\/\/doi.org\/10.1159\/000322787","journal-title":"Neuroendocrinology"},{"key":"9794_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1677\/JOE-07-0020","volume":"194","author":"A Fratticci","year":"2007","unstructured":"Fratticci A, Grieco FA, Spilioti C, Giangaspero F, Ventura L, Esposito V, Piccirilli M, Santoro A, Gulino A, Cantore G, Alesse E, Jaffrain-Rea ML (2007) Differential expression of neurogenins and NeuroD1 in human pituitary tumours. J Endocrinol 194:475\u2013484. https:\/\/doi.org\/10.1677\/JOE-07-0020","journal-title":"J Endocrinol"},{"key":"9794_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1530\/ERC-12-0322","volume":"20","author":"M-L Jaffrain-Rea","year":"2013","unstructured":"Jaffrain-Rea M-L, Rotondi S, Turchi A, Occhi G, Barlier A, Peverelli E, Rostomyan L, Defilles C, Angelini M, Oliva M-A, Ceccato F, Maiorani O, Daly AF, Esposito V, Buttarelli F, Figarella-Branger D, Giangaspero F, Spada A, Scaroni C, Alesse E, Beckers A (2013) Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocr Relat Cancer 20:753\u2013766. https:\/\/doi.org\/10.1530\/ERC-12-0322","journal-title":"Endocr Relat Cancer"},{"key":"9794_CR22","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.3171\/2020.3.FOCUS20114","volume":"48","author":"AF Haddad","year":"2020","unstructured":"Haddad AF, Young JS, Oh T, Pereira MP, Joshi RS, Pereira KM, Osorio RC, Donohue KC, Peeran Z, Sudhir S, Jain S, Beniwal A, Chopra AS, Sandhu NS, Theodosopoulos PV, Kunwar S, El-Sayed IH, Gurrola J, Blevins LS, Aghi MK (2020) Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution. Neurosurg Focus 48:E13. https:\/\/doi.org\/10.3171\/2020.3.FOCUS20114","journal-title":"Neurosurg Focus"},{"key":"9794_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/nan.12675","volume":"47","author":"RA Hickman","year":"2021","unstructured":"Hickman RA, Bruce JN, Otten M, Khandji AG, Flowers XE, Siegelin M, Lopes B, Faust PL, Freda PU (2021) Gonadotroph tumours with a low SF-1 labelling index are more likely to recur and are associated with enrichment of the PI3K-AKT pathway. Neuropathol Appl Neurobiol 47:415\u2013427. https:\/\/doi.org\/10.1111\/nan.12675","journal-title":"Neuropathol Appl Neurobiol"},{"key":"9794_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","volume":"37","author":"M Neou","year":"2020","unstructured":"Neou M, Villa C, Armignacco R, Jouinot A, Raffin-Sanson M-L, Septier A, Letourneur F, Diry S, Diedisheim M, Izac B, Gaspar C, Perlemoine K, Verjus V, Bernier M, Boulin A, Emile J-F, Bertagna X, Jaffrezic F, Laloe D, Baussart B, Bertherat J, Gaillard S, Assi\u00e9 G (2020) Pangenomic Classification of Pituitary Neuroendocrine Tumors. Cancer Cell 37:123-134.e5. https:\/\/doi.org\/10.1016\/j.ccell.2019.11.002","journal-title":"Cancer Cell"},{"key":"9794_CR25","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1210\/mend.14.8.0507","volume":"14","author":"UB Kaiser","year":"2000","unstructured":"Kaiser UB, Halvorson LM, Chen MT (2000) Sp1, steroidogenic factor 1 (SF-1), and early growth response protein 1 (egr-1) binding sites form a tripartite gonadotropin-releasing hormone response element in the rat luteinizing hormone-beta gene promoter: an integral role for SF-1. Mol Endocrinol 14:1235\u20131245. https:\/\/doi.org\/10.1210\/mend.14.8.0507","journal-title":"Mol Endocrinol"},{"key":"9794_CR26","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/s1357-2725(97)00082-4","volume":"29","author":"P Brown","year":"1997","unstructured":"Brown P, Mcneilly AS (1997) Steroidogenic factor-1 (SF-1) and the regulation of expression of luteinising hormone and follicle stimulating hormone b-subunits in the sheep anterior pituitary in vivo. Int J Biochem Cell Biol 29:1513\u20131524. https:\/\/doi.org\/10.1016\/s1357-2725(97)00082-4","journal-title":"Int J Biochem Cell Biol"},{"key":"9794_CR27","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3109\/07435800009048639","volume":"26","author":"M Bakke","year":"2000","unstructured":"Bakke M, Zhao L, Hanley NA, Parker KL (2000) Approaches to define the role of SF-1 at different levels of the hypothalamic-pituitary-steroidogenic organ axis. Endocr Res 26:1067\u20131073. https:\/\/doi.org\/10.3109\/07435800009048639","journal-title":"Endocr Res"},{"key":"9794_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/s0039-128x(98)00031-2","volume":"63","author":"VB Mahesh","year":"1998","unstructured":"Mahesh VB, Brann DW (1998) Neuroendocrine mechanisms underlying the control of gonadotropin secretion by steroids. Steroids 63:252\u2013256. https:\/\/doi.org\/10.1016\/s0039-128x(98)00031-2","journal-title":"Steroids"},{"key":"9794_CR29","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1210\/jcem.86.6.7531","volume":"86","author":"SJ Aylwin","year":"2001","unstructured":"Aylwin SJ, Welch JP, Davey CL, Geddes JF, Wood DF, Besser GM, Grossman AB, Monson JP, Burrin JM (2001) The relationship between steroidogenic factor 1 and DAX-1 expression and in vitro gonadotropin secretion in human pituitary adenomas. J Clin Endocrinol Metab 86:2476\u20132483. https:\/\/doi.org\/10.1210\/jcem.86.6.7531","journal-title":"J Clin Endocrinol Metab"},{"key":"9794_CR30","doi-asserted-by":"publisher","first-page":"e59058","DOI":"10.1371\/journal.pone.0059058","volume":"8","author":"J Fortin","year":"2013","unstructured":"Fortin J, Kumar V, Zhou X, Wang Y, Auwerx J, Schoonjans K, Boehm U, Boerboom D, Bernard DJ (2013) NR5A2 regulates Lhb and Fshb transcription in gonadotrope-like cells in vitro, but is dispensable for gonadotropin synthesis and fertility in vivo. PLoS One 8:e59058. https:\/\/doi.org\/10.1371\/journal.pone.0059058","journal-title":"PLoS One"},{"key":"9794_CR31","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/cancers12041012","volume":"12","author":"MD Ilie","year":"2020","unstructured":"Ilie MD, Vasiljevic A, Louvet C, Jouanneau E, Raverot G (2020) Gonadotroph Tumors Show Subtype Differences that Might Have Implications for Therapy. Cancers 12:1012. https:\/\/doi.org\/10.3390\/cancers12041012","journal-title":"Cancers"},{"key":"9794_CR32","doi-asserted-by":"publisher","first-page":"E708","DOI":"10.1152\/ajpendo.00546.2011","volume":"303","author":"G Trivellin","year":"2012","unstructured":"Trivellin G, Butz H, Delhove J, Igreja S, Chahal HS, Zivkovic V, McKay T, Pat\u00f3cs A, Grossman AB, Korbonits M (2012) MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro. Am J Physiol Endocrinol Metab 303:E708-719. https:\/\/doi.org\/10.1152\/ajpendo.00546.2011","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"9794_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1046\/j.1365-2265.2000.01088.x","volume":"53","author":"HE Turner","year":"2000","unstructured":"Turner HE, Nagy Z, Sullivan N, Esiri MM, Wass JA (2000) Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clin Endocrinol (Oxf) 53:337\u2013344. https:\/\/doi.org\/10.1046\/j.1365-2265.2000.01088.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9794_CR34","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1677\/ERC-09-0101","volume":"16","author":"D Dworakowska","year":"2009","unstructured":"Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, G\u00f3th MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M, Grossman AB (2009) Activation of RAF\/MEK\/ERK and PI3K\/AKT\/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 16:1329\u20131338. https:\/\/doi.org\/10.1677\/ERC-09-0101","journal-title":"Endocr Relat Cancer"},{"key":"9794_CR35","first-page":"2133","volume":"5","author":"NA Hibberts","year":"1999","unstructured":"Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN, Farrell WE (1999) Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin Cancer Res 5:2133\u20132139","journal-title":"Clin Cancer Res"},{"key":"9794_CR36","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/eje.0.143r001","volume":"143","author":"S Jordan","year":"2000","unstructured":"Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB (2000) Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol 143:R1-6. https:\/\/doi.org\/10.1530\/eje.0.143r001","journal-title":"Eur J Endocrinol"},{"key":"9794_CR37","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/carcin\/22.8.1149","volume":"22","author":"DJ Simpson","year":"2001","unstructured":"Simpson DJ, Frost SJ, Bicknell JE, Broome JC, McNicol AM, Clayton RN, Farrell WE (2001) Aberrant expression of G(1)\/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis 22:1149\u20131154. https:\/\/doi.org\/10.1093\/carcin\/22.8.1149","journal-title":"Carcinogenesis"},{"key":"9794_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mce.2010.03.017","volume":"326","author":"M Mu\u015fat","year":"2010","unstructured":"Mu\u015fat M, Morris DG, Korbonits M, Grossman AB (2010) Cyclins and their related proteins in pituitary tumourigenesis. Mol Cell Endocrinol 326:25\u201329. https:\/\/doi.org\/10.1016\/j.mce.2010.03.017","journal-title":"Mol Cell Endocrinol"},{"key":"9794_CR39","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11102-017-0803-0","volume":"20","author":"M Gruppetta","year":"2017","unstructured":"Gruppetta M, Formosa R, Falzon S, Ariff Scicluna S, Falzon E, Degeatano J, Vassallo J (2017) Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas. Pituitary 20:358\u2013371. https:\/\/doi.org\/10.1007\/s11102-017-0803-0","journal-title":"Pituitary"},{"key":"9794_CR40","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1177\/002215540104900916","volume":"49","author":"H Nakabayashi","year":"2001","unstructured":"Nakabayashi H, Sunada I, Hara M (2001) Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. J Histochem Cytochem 49:1193\u20131194. https:\/\/doi.org\/10.1177\/002215540104900916","journal-title":"J Histochem Cytochem"},{"key":"9794_CR41","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s12020-020-02402-5","volume":"70","author":"EB Lamback","year":"2020","unstructured":"Lamback EB, Guterres A, Barbosa MA, Lima, C.H.D.A., Silva, D.A., Camacho, A.H.D.S., Chimelli, L., Kasuki, L. and Gadelha, M.R. (2020) Cyclin A in nonfunctioning pituitary adenomas. Endocrine 70:380\u2013387. https:\/\/doi.org\/10.1007\/s12020-020-02402-5","journal-title":"Endocrine"},{"key":"9794_CR42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jocn.2017.05.005","volume":"43","author":"P Zhao","year":"2017","unstructured":"Zhao P, Zhang P, Hu W, Wang H, Yu G, Wang Z, Li C, Bai J, Zhang Y (2017) Upregulation of cyclin B1 plays potential roles in the invasiveness of pituitary adenomas. J Clin Neurosci 43:267\u2013273. https:\/\/doi.org\/10.1016\/j.jocn.2017.05.005","journal-title":"J Clin Neurosci"},{"key":"9794_CR43","doi-asserted-by":"publisher","first-page":"111140","DOI":"10.1016\/j.mce.2020.111140","volume":"525","author":"J Cheng","year":"2021","unstructured":"Cheng J, Nie D, Li B, Gui S, Li C, Zhang Y, Zhao P (2021) CircNFIX promotes progression of pituitary adenoma via CCNB1 by sponging miR-34a -5p. Mol Cell Endocrinol 525:111140. https:\/\/doi.org\/10.1016\/j.mce.2020.111140","journal-title":"Mol Cell Endocrinol"},{"key":"9794_CR44","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s41416-022-01964-7","volume":"127","author":"O Haworth","year":"2022","unstructured":"Haworth O, Korbonits M (2022) AIP: A double agent? The tissue-specific role of AIP as a tumour suppressor or as an oncogene. Br J Cancer 127:1175\u20131176. https:\/\/doi.org\/10.1038\/s41416-022-01964-7","journal-title":"Br J Cancer"},{"key":"9794_CR45","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1080\/15384101.2015.1064207","volume":"14","author":"P M\u00fcssnich","year":"2015","unstructured":"M\u00fcssnich P, Raverot G, Jaffrain-Rea M-L, Fraggetta F, Wierinckx A, Trouillas J, Fusco A, D\u2019Angelo D (2015) Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors. Cell Cycle 14:2590\u20132597. https:\/\/doi.org\/10.1080\/15384101.2015.1064207","journal-title":"Cell Cycle"},{"key":"9794_CR46","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1073\/pnas.96.5.2147","volume":"96","author":"SA Innocente","year":"1999","unstructured":"Innocente SA, Abrahamson JLA, Cogswell JP, Lee JM (1999) p53 regulates a G2 checkpoint through cyclin B1. Proceedings of the National Academy of Sciences 96:2147\u20132152. https:\/\/doi.org\/10.1073\/pnas.96.5.2147","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"9794_CR47","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1038\/s41467-020-16597-8","volume":"11","author":"DW Hagey","year":"2020","unstructured":"Hagey DW, Topcic D, Kee N, Reynaud F, Bergsland M, Perlmann T, Muhr J (2020) CYCLIN-B1\/2 and -D1 act in opposition to coordinate cortical progenitor self-renewal and lineage commitment. Nat Commun 11:2898. https:\/\/doi.org\/10.1038\/s41467-020-16597-8","journal-title":"Nat Commun"},{"key":"9794_CR48","volume-title":"Caratteristiche cliniche e molecolari dei tumori neuroendocrini gonadotropinici (Gn-PitNETs) in base ai sottogruppi definiti dalla WHO XII Incontri Italiani malattie Ipotalamo-Ipofisarie (4I), 9-11 February","author":"F Carbonara","year":"2023","unstructured":"Carbonara F, Feola T, Gianno F, De Angelis M, Morace R, Giangaspero F, Jaffrain-Rea ML (2023) Caratteristiche cliniche e molecolari dei tumori neuroendocrini gonadotropinici (Gn-PitNETs) in base ai sottogruppi definiti dalla WHO XII Incontri Italiani malattie Ipotalamo-Ipofisarie (4I), 9-11 February. Genova, Italy"},{"key":"9794_CR49","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/COC.0000000000000505","volume":"42","author":"RL Batista","year":"2019","unstructured":"Batista RL, Musolino NRC, Cescato VAS, da Silva GO, Medeiros RSS, Herkenhoff CGB, Trarbach EB, Cunha-Neto MB (2019) Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial. Am J Clin Oncol 42:221\u2013227. https:\/\/doi.org\/10.1097\/COC.0000000000000505","journal-title":"Am J Clin Oncol"},{"key":"9794_CR50","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/EO-22-0055","volume":"2","author":"D Treppiedi","year":"2022","unstructured":"Treppiedi D, Catalano R, Mangili F, Mantovani G, Peverelli E (2022) Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer. Endocr Oncol 2:R143\u2013R152. https:\/\/doi.org\/10.1530\/EO-22-0055","journal-title":"Endocr Oncol"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-023-09794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-023-09794-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-023-09794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T07:29:04Z","timestamp":1710574144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-023-09794-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["9794"],"URL":"https:\/\/doi.org\/10.1007\/s12022-023-09794-w","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"20 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed according to the guidelines of the Declaration of Helsinki and approved by the Internal Review Board of the Neuromed IRCCS (Pozzilli, Italy).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}